Released Nov 13, 2012, before the open
10-Q filed Nov 13, 2012, 44 days after period end · 0001193125-12-465472
Q3 2012 · 10-Q
Revenue$2.17M$2.17M no prior Q3 2011 on file−36.0% vs Q2 2012
Net Income-$18.03M-$18.03M N/M vs Q3 2011N/M vs Q2 2012
EPS Diluted-$0.09-$0.09 N/M vs Q3 2011N/M vs Q2 2012
Gross Profit$1,454,000—
Operating Income-$5,528,000—
Operating Cash Flowderived-$4,165,000N/M
Margins · derived
Gross margin67.1%
Operating margin-255.2%
Net margin-832.2%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2012 | Q3 2011 | Q3 2010 |
|---|---|---|---|
| Revenue | $2.17M | — | — |
| Net Income | -$18.03M | -$5.48M | -$4.14M |
| EPS Diluted | -$0.09 | -$0.14 | -$0.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR